Novo Nordisk is set to report its Q3 results on Wednesday, its first under new CEO Mike Doustdar. Analysts expect revenue to dip 2% to $11.87 billion and profits to fall amid cooling obesity demand and fierce competition from Eli Lilly. The report follows Pfizer's legal push over Novo's $9 billion Metsera bid and investor focus on restructuring plans.